Biomea Fusion

BIOMEA FUSION INC

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

BMEA

Biotech

News

Health Care

Movers

Trading Ideas

General

Biomea Fusion&#39;s COVALENT-111 study shows icovamenib reduces HbA1c significantly in T2D patients, with no safety concerns or drug interactions.

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

Earnings

Markets

ALAB

ALTM

ARRY

CHWY

GTLB

HELE

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

LAZR

NCLH

SGML

SMCI

Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday

investor charts ai2

Pre-Market Outlook

CAPR

IGMS

PMTS

UXIN

IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Biomea Fusion Inc

Press Releases

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Biomea Fusion, Inc. Reports Inducement Grant under  Nasdaq Listing Rule 5635(c)(4)

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Management

Biomea Fusion Announces Leadership Transition

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

bluebird bio

Celularity

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Forte Biosciences

Gain Therapeutics

Immix Biopharma

MAIA Biotechnology

Seres Therapeutics

Metagenomi

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Renovaro

Rein Therapeutics

Repare Therapeutics

Serina Therapeutics

Skye Bioscience

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

D. Boral Capital

HC Wainwright & Co.

Barclays

Piper Sandler

EF Hutton

Comments

Biomea Fusion

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell